【摘要】 目的探讨改良R/ACVBP方案治疗年轻高危侵袭性淋巴瘤的疗效及耐受性。方法入组采用改良R/ACVBP方案治疗的年轻高危侵袭性淋巴瘤患者21例,其中4例合并使用美罗华。结果 21例患者中,17例CR,3例PR,1例PD,总有效率95.2%(20/21),CR率81.0%(17/21),截至随访日期,已死亡6例,5例死于本病,1例死于肝功能衰竭;中位随访42个月,3 a总生存率71.4%。13例出现Ⅲ、Ⅳ度粒细胞减少;3例出现Ⅲ、Ⅳ度血红蛋白减少;1例出现Ⅲ度血小板减少;5例合并感染,其中3例为间质性肺炎并感染;7例出现Ⅲ、Ⅳ度肝功能异常,其中6例为转氨酶升高,1例胆红素、转氨酶同时升高。结论改良R/ACVBP方案治疗年轻高危侵袭性淋巴瘤疗效好,但骨髓抑制及继发感染明显,继续应用该方案须谨慎。更多还原

【Abstract】 Objective To evaluate the efficacy and toxicities of modified R/ACVBP regimen for young high-risk aggressive lymphoma. Methods Twenty-one patients with young high-risk aggressive lymphoma were involved in this study,these patients were treated with modified R / ACVBP regimen,and 4 patients were combined with rituximab. Results Of the 21 patients,17 patients CR were observed,3 patients PR,1 patient PD,the response rate was 95. 2%( 20 /21),the CR rate was 81. 0%( 17 /21). In the follow-up period,6 patients died( 5 patients died of the disease,1patient died of liver failure),the 3-year overall survival rate was 71. 4%. Grade Ⅲ and Ⅳ neutropenia was seen in the13 patients,grade Ⅲ and Ⅳ anemia in the 3 patients,and grade Ⅲ thrombocytopenia was in the 1 patient; infection was found in the 5 patients,including 3 patients interstitial pneumonia; grade Ⅲ and Ⅳ liver function abnormalities were observed in the 7 patients,including 6 patients of elevated transaminases,1 patient of elevated transaminases and bilirubin simultaneously. Conclusion Modified R / ACVBP regimen is highly effective for young high-risk aggressive lymphoma,while significant myelosuppression are observed.更多还原